emtricitabine + tenofovir disoproxil fumarate + omalizumab

This is a combination of three drugs with distinct mechanisms and indications: - **Emtricitabine** is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase, blocking viral replication. - **Tenofovir disoproxil fumarate** is a nucleotide reverse transcriptase inhibitor (NtRTI), also targeting HIV-1 reverse transcriptase to prevent viral DNA synthesis. - The fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate is widely used for the treatment and pre-exposure prophylaxis (PrEP) of HIV infection[1][2][3][4][6]. - **Omalizumab** is a recombinant humanized monoclonal antibody that binds to immunoglobulin E (IgE), preventing its interaction with the high-affinity IgE receptor on mast cells and basophils. This action reduces allergic inflammation, making it effective in conditions like moderate-to-severe persistent asthma and chronic spontaneous urticaria. There are no known approved or established clinical uses for this specific triple combination. Each component has well-established individual or dual-combination uses, but there are no data supporting their combined use as a single regimen.